Platinum-based chemotherapeutic agents cisplatin and carboplatin are widely used in
cancer treatment worldwide and may result in ototoxic hearing loss. The high incidence of …

Ototoxicity is a well‐established toxicity associated with a subgroup of antineoplastic
therapies that includes platinum chemotherapy, radiation or surgery involving the ear and …

Children treated for malignancies may be at risk for early-or delayed-onset hearing loss that
can affect learning, communication, school performance, social interaction, and overall …

Purpose Carboplatin-induced ototoxicity remains poorly defined but is of potential great
consequence in children with retinoblastoma. We retrospectively assessed the incidence of …

PURPOSE: To report on our 3-year experience with the use of superselective ophthalmic
artery infusion of chemotherapy as initial, primary treatment for intraocular retinoblastoma …

Childhood, adolescent, and young adult (CAYA) cancer survivors treated with platinum-
based drugs, head or brain radiotherapy, or both have an increased risk of ototoxicity …

Background To evaluate outcomes of Group D eyes of bilateral retinoblastoma patients
treated with primary chemoreduction and external beam radiation as salvage. Procedure …

Background Carboplatin plays an important role in the conservative management of
retinoblastoma, but is associated with risk of ototoxicity in these young children whose …

Purpose: To evaluate the potential utility of histone deacetylase inhibitors (HDACi) for
treatment of retinoblastoma (RB). Experimental Design: Growth-inhibitory effects of HDACi …

Background Retinoblastoma occurs in approximately 4 per million children per year in the
United States, usually before 2 years of age. In developed countries, 95% of children with …